Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer
March 05, 2020 16:01 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob...
Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 18, 2020 08:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President...
Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain
January 28, 2020 16:05 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results...
Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
November 26, 2019 07:00 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, Satsuma...
Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results
November 12, 2019 16:01 ET
|
Satsuma Pharmaceuticals
Completed upsized initial public offering of $90.8 million in gross proceeds Dosed first patient in Phase 3 EMERGE™ efficacy trial of STS101 for the acute treatment of migraine Presented STS101...